Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Insists Complex Generics Strategy Is Poised To Deliver

Executive Summary

With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.


Related Content

Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
Teva CEO Schultz Walks Smack Into A Rough Financial Situation
Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Will FDA GMP Observations Stall Biocon’s Run?
Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There
Generic Manufacturers Try To Up Their Game As US Pressure Persists
Mylan Takes Issue With FDA Over 'Major' CRL For Advair Generic


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts